Evaluation of pharmacotherapy recommendations in guidelines for inflammatory bowel disease
Open Access
- 5 February 2021
- journal article
- review article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (3) , 599-609
Abstract
What is known and objective The aim of this study was to systematically assess drug therapy in the guidelines for inflammatory bowel disease and to provide recommendations for the development of such guidelines. Study design A systematic search was conducted in databases and on websites to identify guidelines for the treatment of inflammatory bowel disease. Qualified guidelines were assessed through the Appraisal of Guidelines for Research and Evaluation (AGREE II). Evidence from the guidelines was extracted from the guidelines themselves. The Oxford Centre for Evidence‐based Medicine (OCEBM) evidence grading system was used to regrade and assess this evidence. Results A total of 11 guidelines for the medical treatment of inflammatory bowel disease (Crohn's disease and ulcerative colitis) (2015–2019) were finally included, and after scoring using the AGREE II tool, the median scores in each domain were as follows: Ⅰ. scope and purpose (median score=88.9%, range: 76.4%‐91.7%), Ⅱ. stakeholder involvement (median =38.9%, range: 18.1%‐61.1%), Ⅲ. rigour of development (median =69.3%, range: 39.6%‐77.6%), Ⅳ. clarity and presentation (median =97.2%, range: 91.7%‐100%), Ⅴ. applicability (median =45.8%, range: 24%‐68.8%) and Ⅵ. editorial independence (median =94.0%, range: 0–100%). Most of the guidelines scored over 60%, which is worthy of clinical recommendation, but different guidelines suggest that there is a great difference in drug therapy, mainly due to various populations, diverse focuses of attention, distinct efficacy of drugs between Crohn's disease and ulcerative colitis, and the preference of guiding developers for select evidence. What is new and conclusion The quality of medical treatment guidelines for inflammatory bowel disease varies considerably. Over the past 5 years, medical treatment has been heterogeneous among different guidelines. Consideration of factors leading to heterogeneity of recommendations for drug treatment, especially preferences for evidence selection, will help upgrade the guidelines.Keywords
This publication has 15 references indexed in Scilit:
- ACG Clinical Guideline: Management of Crohn's Disease in AdultsAmerican Journal of Gastroenterology, 2018
- Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopáticaRevista de Gastroenterología de México, 2018
- Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de CrohnGastroenterología y Hepatología, 2017
- ACG Clinical Guideline: Preventive Care in Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2017
- The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in PregnancyGastroenterology, 2016
- Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto ConsensusGastroenterology, 2015
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic ReviewGastroenterology, 2012
- Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-AnalysisAmerican Journal of Gastroenterology, 2011
- Heterogeneity in cancer guidelines: should we eradicate or tolerate?Annals of Oncology, 2008
- Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trialGastroenterology, 1996